Literature DB >> 3731132

Identification of human urinary mitoxantrone metabolites.

F S Chiccarelli, J A Morrison, D B Cosulich, N A Perkinson, D N Ridge, F W Sum, K C Murdock, D L Woodward, E T Arnold.   

Abstract

Two polar metabolites of mitoxantrone, a clinically active antitumor agent, have been isolated and purified from the urine of patients by sequential absorption on glass wool and C18-Sep-Pak cartridges followed by preparative high-performance liquid chromatography. Negative ion chemical ionization mass spectrometry indicated that the two metabolites are the di- and mono-carboxylic acids resulting from oxidation of the terminal hydroxyl groups of the side chain(s). Mass spectral comparison of the urinary metabolites with synthetic compounds confirmed the identification.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731132

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

2.  Studies towards the synthesis of dicarboxylic acid metabolite of mitoxantrone: PS177.

Authors:  Ivanna Hrynchak; Emília Sousa; Maria de Lourdes Bastos; Madalena Pinto; Vera Marisa Costa
Journal:  Porto Biomed J       Date:  2017-09-01

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 5.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 6.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

7.  Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells.

Authors:  Ana Reis-Mendes; Félix Carvalho; Fernando Remião; Emília Sousa; Maria de Lourdes Bastos; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2022-10-10       Impact factor: 6.168

Review 8.  Mitoxantrone: a review of its use in multiple sclerosis.

Authors:  Lesley J Scott; David P Figgitt
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

10.  Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  B Richard; M C Launay-Iliadis; A Iliadis; S Just-Landi; D Blaise; A M Stoppa; P Viens; M H Gaspard; D Maraninchi; J P Cano
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.